EID Parry Q1 FY27 Standalone Loss ₹89 Crore

Revenue from Operations: ₹73,312 lakhs (Q1 FY26: ₹75,591 lakhs) - decreased 3.0% YoY
Total Income: ₹75,200 lakhs (Q1 FY26: ₹80,038 lakhs)
EBITDA (Operational): Loss of ₹2,300 lakhs (Q1 FY26: Loss of ₹1,900 lakhs)
Profit/(Loss) Before Tax: Loss of ₹10,987 lakhs (Q1 FY26: Loss of ₹5,330 lakhs)
Exceptional Items: ₹1,868 lakhs charge (related to PSRIPL impairment)
Profit/(Loss) After Tax: Loss of ₹8,929 lakhs (₹89 crore) (Q1 FY26: Loss of ₹2,792 lakhs)
Basic EPS: Negative ₹5.02 (Q1 FY26: Negative ₹1.57)

Revenue from Operations: ₹901,752 lakhs (₹9,017 crore) (Q1 FY26: ₹871,975 lakhs) - increased 3.4% YoY
Profit Before Tax: ₹42,286 lakhs (Q1 FY26: ₹61,542 lakhs) - decreased 31.3% YoY
Profit After Tax and Non-Controlling Interest: ₹14,160 lakhs (₹142 crore) (Q1 FY26: ₹24,628 lakhs) - decreased 42.5% YoY

Sugar: ₹40,978 lakhs (Q1 FY26: ₹34,654 lakhs) - increased 18.2% YoY
Co-generation: ₹666 lakhs (Q1 FY26: ₹753 lakhs)
Distillery: ₹25,482 lakhs (Q1 FY26: ₹29,528 lakhs) - decreased 13.7% YoY
Nutraceuticals: ₹622 lakhs (Q1 FY26: ₹594 lakhs)
Consumer Products: ₹9,420 lakhs (Q1 FY26: ₹18,799 lakhs) - decreased 49.9% YoY

Sugar: Loss of ₹4,867 lakhs (Q1 FY26: Loss of ₹4,902 lakhs)
Co-generation: Loss of ₹2,193 lakhs (Q1 FY26: Loss of ₹1,950 lakhs)
Distillery: Profit of ₹866 lakhs (Q1 FY26: Profit of ₹2,027 lakhs) - decreased 57.3% YoY
Nutraceuticals: Profit of ₹1 lakh (Q1 FY26: Loss of ₹20 lakhs)
Consumer Products: Loss of ₹1,198 lakhs (Q1 FY26: Loss of ₹1,747 lakhs)

The company allotted 82,975 equity shares during the quarter ended June 30, 2026, pursuant to exercise of stock options by employees (Q1 FY26: 17,790 shares)
Paid-up equity share capital stands at ₹1,779 lakhs (unchanged from previous quarter)

Impairment of investment in subsidiary: ₹61,000 lakhs charge
Reversal of financial guarantee obligation: ₹59,132 lakhs credit
Net additional impairment charge: ₹1,868 lakhs for Q1 FY27
The company committed to provide additional financial support to PSRIPL in form of loans up to ₹13,000 lakhs, of which ₹5,500 lakhs was disbursed during the quarter

Reversal of impairment in Alimtec SA: ₹116 lakhs credit (year-ended March 31, 2026)
Reversal of impairment in Algavista Greentech: ₹105 lakhs credit (year-ended March 31, 2026)
Gain on sale of Coromandel International shares: ₹29,764 lakhs (year-ended March 31, 2026)
Impairment of property, plant and equipment: ₹13,769 lakhs charge (year-ended March 31, 2026)

Parry Sugars Refinery India Private Limited ceased operations effective close of business hours on March 31, 2026
Closure due to adverse global market conditions, higher operating costs, and operational disruptions
The subsidiary was engaged in refining raw sugar and exporting refined sugar
All bank loans fully repaid, employee obligations discharged
Process for exit from SEZ and statutory requirements progressing
Identification of potential purchasers for asset sale in progress

Price Waterhouse Chartered Accountants LLP conducted limited review of both standalone and consolidated results
Unmodified conclusion provided - no material misstatements found
Financial results prepared in accordance with Ind AS 34 and SEBI Listing Regulations

Mr. Muthiah Murugappan, Whole-time Director and CEO, highlighted:

Sugar & Biofuels: Resilient quarter despite headwinds from lower ENA quotas, falling realizations, and elevated input costs
Consumer Products: Strategic transformation focusing on profitable growth, premiumization, and distribution expansion
Nutraceuticals: Steady performance despite temporary challenges in key export markets
US Nutraceuticals: Strong performance supported by robust growth in Pet Health segment and new product launches
Overall Focus: 'Disciplined Renewal' to strengthen core operations and drive operational excellence

Document contains forward-looking statements subject to risks and uncertainties. Company undertakes no obligation to update these statements.